PYXS 8-K 2026-11-05

Pyxis Oncology, Inc. (PYXS) 8-K dated 2026-11-05 — accession 0001193125-26-448604.

Pyxis Oncology, Inc. (PYXS) is a biotechnology company listed on NASDAQ.

PYXS: Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlig…

This 8-K covers: Results of operations (Item 2.02). SEC EDGAR holds the official filing and its exhibits.

Latest reported PYXS revenue for 2025-12-31 was $13.9M. Net income was -$79.6M. PYXS currently screens at market cap $109.6M.

Not investment advice. The PYXS SEC hub lists recent forms. The stock page is the research view.